Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

在生物制药板块面临挑战的背景下，Cassava Sciences Inc. (SAVA)的股价已跌至52周低点，触及3.35美元。根据 InvestingPro 的数据，该公司保持着3.55的健康流动比率，且现金多于债务，尽管技术指标显示该股票目前处于超卖状态。作为神经退行性疾病药物研发的前沿公司，Cassava Sciences的股票受到了更广泛的市场逆风和对其管线进展的特定担忧的打击。过去一年 ...